# The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease

> **NCT01738035** · PHASE2 · COMPLETED · sponsor: **Calliditas Therapeutics AB** · enrollment: 150 (actual)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** NEFECON
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01738035
- **Lead sponsor:** Calliditas Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-06
- **Final completion:** 2015-09
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2015-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01738035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01738035, "The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01738035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*